COVID-19 and Endocrinology

Dear Colleagues,

More than 30 months have passed since the state of pandemic was declared on March 2022. Since then, more than 600 million confirmed cases and over 6 million deaths have been registered worldwide. Diabetes mellitus, morbid obesity, male hypogonadism, hypercortisolism, hypoadrenalism, and undernourishment were found to be risk factors of a worse prognosis in COVID-19. In addition, SARS-CoV-2 could be involved in the pathogenesis of newly onset or relapsing endocrine diseases, such as subacute or silent thyroiditis and chronic autoimmune thyroiditis.

Vaccines have significantly improved the prognosis of COVID-19, particularly in those patients at high risk of severe complications. However, the worldwide vaccine coverage is heterogeneous, especially considering unequal vaccine access between high- and low-income countries, vaccine hesitancy, and the need for a periodic boosting of vaccinated people due to the progressive loss in vaccine protection over time. Given this background, although clinical manifestations and the incidence of severe outcomes of COVID-19 are declining, especially in places where vaccination coverage is high, complete control of SARS-CoV-2 transmission is probably far from being achieved despite wide seasonal variability.

The number of patients who have contracted the infection is considerable, and a continual increase in this number over time is also expected. Hence, this is a current topic that warrants further exploration. The aim of this Special Issue is to provide updated information about the role of SARS-CoV-2 in the pathogenesis of acute, subacute, and chronic endocrine diseases and dysfunction, vaccine efficacy/effectiveness and safety from an endocrinological point of view, and endocrine diseases and dysfunction as possible prognostic factors of worse outcomes in COVID-19. Original case reports, case series, retrospective and prospective clinical studies, systematic reviews, and meta-analyses could be considered suitable for publication.

Dr. Giuseppe Lisco
Dr. Vincenzo Triggiani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Endocrines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• COVID-19
• SARS-CoV-2
• SARS-CoV-2 vaccines
• hypopituitarism
• hypercortisolism
• hypoadrenalism
• thyroiditis
• diabetes mellitus
• obesity
• male hypogonadism
• vitamin D
• undernourishment